Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 12/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.38 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13252743 | 0.87 | DGAT1 (0.41) | BRAFDGAT1MAP4K1SCN9AMAP3K5 | |
| SCHEMBL13252105 | 0.81 | PRKCQ (0.46) | BRAFDGAT1MAP3K5KDR | |
| SCHEMBL12671180 | 0.81 | JAK3 (0.51) | BRAFDGAT1 | |
| SCHEMBL13252759 | 0.76 | MAP4K1 (0.50) | MAP4K1MAP4K3 | |
| SCHEMBL13362919 | 0.74 | DGAT1 (0.41) | BRAFDGAT1MAP4K1SCN9AMAP3K5 | |
| SCHEMBL12671463 | 0.73 | MAP4K1 (0.51) | MAP4K1MAP4K3KDR | |
| SCHEMBL13252104 | 0.73 | MAP4K1 (0.63) | MAP4K1SCN9AMAP4K3 | |
| SCHEMBL13362982 | 0.72 | SYK (0.45) | DGAT1MAP4K1SCN9A | |
| SCHEMBL13362987 | 0.72 | MAP3K5 (0.62) | BRAFMAP3K5KDR | |
| SCHEMBL13252757 | 0.71 | HTR2C (0.50) | BRAFDGAT1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRAF 316/4885DGAT1 1506/4885MAP4K1 49/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | BRAF 208/4885DGAT1 1001/4885MAP4K1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.